Background: Patients undergoing acute left main (LM) coronary artery revascularization have a high mortality and natriuretic peptides such as N-terminal pro-B-type (NT-proBNP) have been shown to have prognostic value in patients with acute coronary syndromes. The present study looked at the prognostic value of NT-proBNP in these patients.
atients with acute left main (LM) coronary artery disease represent a high-risk population and mortality of LM stenting in the setting of acute coronary syndromes (ACS) is high. 1- 3 Montalescot et al recently reported the results of patients with ACS and LM disease included in the Global Registry of Acute Coronary Events (GRACE) between 2000 and 2007. 4 In this population, overall in-hospital mortality was 7.7%, and for comparison, in-hospital mortality was earlier reported to be 3.7% in the Expanded GRACE registry. 5 LM stenting has been carried out with increasing frequency during the past years. Nevertheless, patients with unprotected LM disease still challenge the interventionist, especially in the setting of ACS. 6,7 Therefore, a parameter allowing for risk stratification of this high-risk patient group may be of great value. Natriuretic peptides such as B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) have been shown to be of prognostic value not only in patients with chronic heart failure, but also in patients with stable coronary artery disease and those with ACS. 8- 10 Therefore, we aimed to examine the prognostic value of NT-proBNP at admission in patients with ACS undergoing acute LM coronary artery percutaneous coronary intervention (PCI).
NT-proBNP in LM PCI for ACS

Methods
Patient Population
The University Hospital Zurich is a tertiary referral clinic treating approximately 450 cases of ACS (ie, unstable angina pectoris and acute myocardial infarction [MI] ) each year. Between January 2005 and December 2008, a total of 86 patients presenting with acute MI or unstable angina underwent acute LM coronary artery stenting. All patients whose NT-proBNP level was determined on the day of admission were included for analysis (n=71). There were no exclusion criteria. Data from in-hospital outcome were collected in all patients and a telephone follow-up was carried out to assess long-term outcome. The study was approved by the local ethics committee. Patients whose NT-proBNP level was not measured presented with a higher creatinine at admission (123±88 and 94±33 μmol/L, P=0.038), had a lower peak creatine kinase and presented more often with a previous MI. Otherwise, patient and procedural characteristics, as well as in-hospital outcome, did not differ.
NT-proBNP
NT-proBNP was determined using a microparticle enzyme immunoassay (Roche Elecsys, Basel, Switzerland). Normal values of NT-proBNP were defined according to age and sexr as published by Galasko et al: ≤100 ng/L for males <60 years, ≤164 ng/L for females <60 years, ≤172 ng/L for males ≥60 years and ≤225 ng/L for females ≥60 years were considered normal. 11
Endpoints
The following endpoints were analyzed: all-cause mortality, cardiovascular mortality (non-cardiovascular deaths were censored at the time of death), the need for target lesion revascularization including unplanned coronary artery bypass grafting (CABG), MI, stent thrombosis and major bleeding, which was defined as intracranial or intraocular hemorrhage; any gastrointestinal hemorrhage; bleeding at the access site (inguinal hematoma ≥5 cm or requiring intervention), retroperitoneal bleeding; urogenital hemorrhage; a need for transfusion of packed red blood cells; a decrease in hemoglobin ≥4 g/dl; any other major bleeding. Definite stent thrombosis was defined according to the Academic Research Consortium classification. 12 
Statistical Analysis
Statistical analysis was performed using SPSS 15 (SPSS Inc, Chicago, IL, USA). Continuous variables are presented as mean ± standard deviation or as median and interquartile ranges (Q1, Q3). Categorical variables are presented as absolute and relative frequencies. Continuous variables were compared between groups using Student's t-test (parametric variables) and Mann-Whitney U test (non-parametric variables). Correlation between lesion severity and NT-proBNP was assessed via Spearman's correlation coefficient, including calculation of the 95% confidence interval (CI) using Fisher transformation. Lesion severity was visually estimated and classified as 0%, 20%, 50%, 70%, 90%, 91-99% and 100%. Categorical variables were compared between groups with the chi-square test Receiver-operating characteristic (ROC) curves were used to assess how well NT-proBNP discriminates between patients who die and patients who survive in hospital. In this exploratory analysis, no correction for multiple testing was done and all P values ≤0.05 were considered statistically significant.
Results
Patients and Procedures
A total of 71 patients (69% males) with a median age of 69 years (interquartile range 62-77 years) were analyzed. Median duration of hospital stay was 6 days (interquartile range 2-13 days, range 1-57 days). Overall, 62% of the patients presented with acute MI and the remaining with unstable angina pectoris; 27 patients (38%) had a previous MI and 21 (30%) a previous CABG. A total of 17 patients (24%) presented in cardiogenic shock (Killip class IV). All patients underwent acute coronary angiography including LM coronary artery stenting. In total, 56 (79%) of the patients had a LM stenosis (≥50%). The culprit vessel was the LM coronary artery in 35 (49%) of the patients, the ostial left anterior descending in 12 (17%) and the ostial circumflex artery in 4 (6%) of the patients. In the remaining 20 patients, stenting of the culprit lesion did not involve the LM coronary artery, but LM stenting was carried out during the same intervention because of relevant stenosis. Table 1 shows the patient characteristics and procedural details for the overall patient population and for patients with a LM coronary artery culprit lesion and for those without. As shown in Table 2 , in-hospital outcome did not differ between these 2 patient groups. All deaths that occurred in hospital were cardiovascular deaths. The 1-year survival was 78% and 83% for patients with a LM culprit lesion and non-LM culprit lesion, respectively (P=0.598). Cardiovascular death occurred in 18% and 9% after 1 year (P=0.162).
NT-pro BNP
Median NT-proBNP level was 1,364 ng/L, ranging from 46 to 70,000 ng/L (interquartile range 280-2,797 ng/L). NT-proBNP was elevated in 63 (89%) of the patients and was ≥1,000 ng/L in 42 (59%) of the patients.
NT-proBNP was significantly higher in patients with cardiogenic shock (2,219 ng/L and 796 ng/L, for patients with and without cardiogenic shock, P=0.003). NT-proBNP was not significantly higher in patients with an intra-arterial balloon pump (1,515 ng/L) than in those without (1,040 ng/L, P=0.275). NTproBNP correlated positively with severity of the LM coronary artery stenosis (ρ=0.31, 95%CI 0.07-0.51, P=0.010). Table 3 shows univariate Cox regression analysis for allcause mortality. Reduced LVEF and increased log NT-proBNP were significantly associated with an increased mortality rate. Log NT-proBNP (HR 4.32, 95%CI 1.43-13.00, P=0.009) and LVEF (HR 0.94, 95%CI 0.90-0.99, P=0.029) were significant predictors of cardiovascular mortality. In multivariate Cox regression analysis using a stepwise backward elimination model, log NT-proBNP (HR 2.36, 95%CI 0.86-6.48, P=0.094) and LVEF (HR 0.96, 95%CI 0.92-1.01, P=0.099) remained in the model as independent predictors for all-cause mortality. Log NT-proBNP was the only significant independent predictor of cardiovascular mortality (HR 4.09, 95%CI 1.28-13.07, P=0.017). We also tested Killip class as a continuous variable (instead of Killip class I-III vs Killip class IV) but the results remained the same (NT-proBNP and LVEF remained as predictors of all-cause mortality, NT-proBNP remained as predictor of cardiovascular mortality).
ROC curves were used to further evaluate the predictive value of NT-proBNP. The area under the curve was 0.763 for in-hospital mortality. An NT-proBNP of 1,000 ng/L yielded a sensitivity of 100% (7/7 patients who died in hospital had an NT-proBNP ≥1,000 ng/L) and a specificity of 45% (29/64 patients who survived in hospital had an NT-proBNP <1,000 ng/L) to identify patients who will die in hospital and was therefore able to identify a subgroup with low mortality (Figure 1) . For further analysis, patients were divided into 2 groups: NTproBNP <1,000 ng/L and NT-proBNP ≥1,000 ng/L. Other abbreviations see in Table 1 . Figure 1 . Receiver-operating characteristics curve showing the prognostic value of NT-proBNP to predict in-hospital mortality. A cut-off of 1,000 ng/L yielded a sensitivity of 100% and a specificity of 45% to identify patients who will die in hospital and was therefore able to identify a subgroup with low mortality. NT-proBNP, N-terminal pro-B-type natriuretic peptide. Outcome in Patients With NT-proBNP <1,000 ng/L and NT-proBNP ≥1,000 ng/L In-hospital mortality was 0% for patients with NT-proBNP <1,000 ng/L and 17% for those with NT-proBNP ≥1,000 ng/L (P=0.036). All of the in-hospital deaths were cardiovascular deaths. One case of acute stent thrombosis occurred in each patient group and both patients survived after urgent revascularization. A total of 4 patients had unplanned in-hospital target lesion revascularization (2 in each group). Figure 2 shows the long-term outcome of the 2 patient groups. At 1 year, 93% of the patients with NT-proBNP <1,000 ng/L and 74% of the patients with NT-proBNP ≥1,000 ng/L were alive (P= 0.039). However, additive mortality between hospital discharge and 1 year did not differ (7% for patients with NT-proBNP <1,000 ng/L and 11% for patients with NT-proBNP ≥1,000 ng/L, P=0.681). The rates of target lesion revascularization at 1 year were 20% for patients with NT-proBNP <1,000 ng/L and 10% for NT-proBNP ≥1,000 ng/L (P=0.449).
NT-proBNP in LM PCI for ACS
Discussion
To our knowledge, this is the first study to investigate the role of NT-proBNP in patients undergoing acute LM coronary artery stenting, LM coronary artery revascularization in patients with ACS is associated with high mortality and such patients are often difficult to manage. Therefore, it is essential to have a parameter that enables risk stratification of these high-risk patients. Our findings indicate that patients undergoing acute LM coronary artery revascularization presenting with a NTproBNP <1,000 ng/L at admission may have an excellent short and long-term survival. In-hospital mortality of this population was 0% and 1-year mortality was as low as 7%. On the other hand, in-hospital mortality in patients with an NT-proBNP ≥1,000 ng/L was 17% and 1-year mortality was 26%. Therefore, it appears that NT-proBNP may help to identify a lowerrisk subgroup in this high-risk population. Indeed, NT-proBNP and LVEF were the only significant predictors of mortality and NT-proBNP was the only independent significant predictor of cardiovascular mortality.
Prognostic Value of NT-proBNP in Patients With ACS
NT-proBNP has been shown to be a reliable biomarker of systolic 13 and diastolic dysfunction. 14 Several studies have investigated the prognostic role of natriuretic peptides in patients with ACS. A rise in the BNP level occurs immediately after myocardial ischemia, 15,16 even before elevation of traditional myocardial necrosis markers. 15 After MI, increased levels of BNP have been associated with the development of LV remodeling and reduced LVEF. 17 The first study that showed an association between NT-proBNP and outcome after ST-elevation MI was published in 1998 and thereafter several studies have shown that NT-proBNP levels obtained in the acute or subacute phase of a non-ST-elevation MI are strongly associated with both short and long-term overall and cardiovascular mortality. 18-22 In 1 study, patients with BNP >101 pg/ml had a 13-fold higher rate of 1-month mortality (P<0.0001) and a 5.3-fold higher rate of 1-year mortality (P<0.0001) than patients with BNP ≤101 pg/ml. 22 In another study by Darbar et al, BNP was the only independent predictor of cardiovascular mortality in patients with acute MI. 23 Khan et al. were able to show that NT-proBNP predicted death after acute MI better than TIMI risk score. 24 In a study by Lorgis et al, NT-proBNP was a significant determinant of cardiovascular mortality in patients older than 54 years but not in the younger. 25 This is in accordance to our results where only 9/71 (13%) were younger than 54 years and none of these patients died during follow-up. In summary, these data and the data from our study suggest that natriuretic peptides such as BNP or NT-proBNP are strong markers of cardiovascular and overall outcome and may outperform the other prognostic parameters TIMI risk score or Killip class. However, this was a clinical study designed to investigate the value of NT-proBNP in patients undergoing acute LM stenting. Although NT-proBNP correlated with severity of LM disease, the study was not designed to investigate the prognostic value of NT-proBNP in patients with different degrees of LM stenosis.
Which Cut-Off Value Is Appropriate for Patients Undergoing Acute LM Revascularization? Different cut-off values for NT-proBNP have been suggested in the literature. We initially used the reference values published by Galasko et al, 11 but found that 89% of the patients had an elevated NT-proBNP. Analysis of the ROC curves showed that a cut-off of 1,000 ng/L was able to identify patients with a favorable in-hospital outcome. Previous studies have shown that NT-proBNP levels are directly related to the complexity and severity of the coronary lesions. In patients with non-STelevation MI, those with LM or 3-vessel disease had a median NT-proBNP of 519 ng/L, which was significantly more than patients with 2-vessel disease (312 ng/L), 1-vessel disease (252 ng/L) or no relevant coronary artery stenosis (121 ng/L). 26 Similar associations between BNP and coronary artery disease complexity have been found in other studies. 27, 28 In our study, the median NT-proBNP was as high as 1,364 ng/L. Our patient population indeed had very complex coronary lesions, including LM, ostial left anterior descending and ostial circumflex lesions, and thus a "normal" cut-off value is not appropriate to identify patients at lower risk.
Study Limitations
This was a retrospective study and NT-proBNP was only determined in 71 of 86 ACS patients with LM disease at hospital admission. Of note, creatinine was higher in patients in whom NT-proBNP was not determined. The reason for this may be that the physician in charge was expecting a high NT-proBNP in the presence of high creatinine levels. In addition, the number of patients was small. Furthermore, we only analyzed NT-proBNP at hospital admission. As suggested by recent studies, 29,30 serial determination of natriuretic peptides may increase the accuracy of predicting late events. However, in our patients, the majority of deaths occurred early and cardiovascular mortality was relatively low in the survivors of both groups after hospital discharge.
Conclusion
Patients undergoing acute LM stenting are at high risk. However, those with NT-proBNP <1,000 ng/L may have a favorable short-and long-term prognosis. Further research, including a larger patient population, is needed to determine the optimal cut-off value for NT-proBNP in patients undergoing acute LM coronary artery PCI.
